Patents by Inventor Wayne Jiang

Wayne Jiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNE MODULATION WITH TLR9 AGONISTS FOR CANCER TREATMENT
    Publication number: 20220088054
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Application
    Filed: December 6, 2021
    Publication date: March 24, 2022
    Inventors: Sudhir AGRAWAL, Daqing WANG, Wayne JIANG
  • Immune modulation with TLR9 agonists for cancer treatment
    Patent number: 11224611
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: January 18, 2022
    Assignee: IDERA PHARMACEUTICALS, INC.
    Inventors: Sudhir Agrawal, Daqing Wang, Wayne Jiang
  • IMMUNE MODULATION WITH TLR9 AGONISTS FOR CANCER TREATMENT
    Publication number: 20210052625
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Application
    Filed: September 14, 2020
    Publication date: February 25, 2021
    Inventors: Sudhir AGRAWAL, Daqing WANG, Wayne JIANG
  • IMMUNE MODULATION WITH TLR9 AGONISTS FOR CANCER TREATMENT
    Publication number: 20210038630
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Application
    Filed: October 21, 2020
    Publication date: February 11, 2021
    Inventors: Sudhir AGRAWAL, Daqing WANG, Wayne JIANG
  • Immune modulation with TLR9 agonists for cancer treatment
    Patent number: 10835550
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: November 17, 2020
    Assignee: IDERA PHARMACEUTICALS, INC.
    Inventors: Sudhir Agrawal, Daqing Wang, Wayne Jiang
  • Immune modulation with TLR9 agonists for cancer treatment
    Patent number: 10772907
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: September 15, 2020
    Assignee: IDERA PHARMACEUTICALS, INC.
    Inventors: Sudhir Agrawal, Daqing Wang, Wayne Jiang
  • IMMUNE MODULATION WITH TLR9 AGONISTS FOR CANCER TREATMENT
    Publication number: 20200138848
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Application
    Filed: August 30, 2019
    Publication date: May 7, 2020
    Inventors: Sudhir AGRAWAL, Daqing WANG, Wayne JIANG
  • TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS
    Publication number: 20200101102
    Abstract: The invention provides methods of inducing an immune response to cancer comprising co-administering to a cancer patient one or more TLR9 agonists and one or more checkpoint inhibitors. Preferably, the one or more TLR9 agonists are administered to the patient via intratumoral (i.t.) administration.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 2, 2020
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Daqing WANG, Wayne JIANG, Sudhir AGRAWAL
  • IMMUNE MODULATION WITH TLR9 AGONISTS FOR CANCER TREATMENT
    Publication number: 20200054663
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Application
    Filed: August 30, 2019
    Publication date: February 20, 2020
    Inventors: Sudhir AGRAWAL, Daqing WANG, Wayne JIANG
  • Immune modulation with TLR9 agonists for cancer treatment
    Patent number: 10463686
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: November 5, 2019
    Assignee: IDERA PHARMACEUTICALS, INC.
    Inventors: Sudhir Agrawal, Daqing Wang, Wayne Jiang
  • IMMUNE MODULATION WITH TLR9 AGONISTS FOR CANCER TREATMENT
    Publication number: 20180125877
    Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
    Type: Application
    Filed: September 15, 2017
    Publication date: May 10, 2018
    Inventors: Sudhir AGRAWAL, Daqing JIANG, Wayne JIANG
  • COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF
    Publication number: 20180044669
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.
    Type: Application
    Filed: October 26, 2017
    Publication date: February 15, 2018
    Inventors: Sudhir AGRAWAL, Wayne JIANG, Daqing Wang, Jessica Seitzer, Fu-Gang Zhu, Xianzhi Mao
  • Compositions for inhibiting checkpoint gene expression and uses thereof
    Patent number: 9828601
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: November 28, 2017
    Assignee: IDERA PHARMACEUTICALS, INC.
    Inventors: Sudhir Agrawal, Wayne Jiang, Daqing Wang, Jessica Seitzer, Fu-Gang Zhu, Xianzhi Mao
  • TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS
    Publication number: 20170274004
    Abstract: The invention provides methods of inducing an immune response to cancer comprising co-administering to a cancer patient one or more TLR9 agonists and one or more checkpoint inhibitors. Preferably, the one or more TLR9 agonists are administered to the patient via intratumoral (i.t.) administration.
    Type: Application
    Filed: June 6, 2017
    Publication date: September 28, 2017
    Inventors: Daqing Wang, Wayne Jiang, Sudhir Agrawal
  • COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF
    Publication number: 20160251652
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.
    Type: Application
    Filed: February 25, 2016
    Publication date: September 1, 2016
    Inventors: Sudhir Agrawal, Wayne Jiang, Daqing Wang, Jessica Seitzer, Fu-Gang Zhu, Xianzhi Mao
  • TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS
    Publication number: 20160101128
    Abstract: The invention provides methods of inducing an immune response to cancer comprising co-administering to a cancer patient one or more TLR9 agonists and one or more checkpoint inhibitors. Preferably, the one or more TLR9 agonists are administered to the patient via intratumoral (i.t.) administration.
    Type: Application
    Filed: October 9, 2015
    Publication date: April 14, 2016
    Inventors: Daqing Wang, Wayne Jiang, Sudhir Agrawal
  • Method and system for computerized learning, response, and evaluation
    Patent number: 5890911
    Abstract: A method and system for computerizing learning, response, and evaluation is provided. The computerized system comprises a central processing unit and related memory and storage capacity to operate a learning, response, and evaluation system stored in a computer program. The learning, response, and evaluation system comprises an authoring portion and a presentation portion. Through the use of intuitive interface elements, the authoring portion allows an author to quickly and easily construct a lesson from a pool of relevant data. Due to the design and capabilities provided, the authoring portion reduces the time it takes for an author to learn how to construct a lesson and reduces the time it takes to construct the lesson. Data can be organized into pages which are presented to the user and pages which are hidden from the user. The presentation portion allows a user to view and learn the information contained in a lesson.
    Type: Grant
    Filed: January 9, 1997
    Date of Patent: April 6, 1999
    Assignee: William M. Bancroft
    Inventors: Michael R. Griswold, Thierry Guillerm, Wayne Jiang, Bruce Mossman, Spencer Rogers, Giovanni Tata
  • Multi-media device stand
    Patent number: D723311
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: March 3, 2015
    Inventors: Wayne Jiang, Brian Jiang
  • Multi-media device stand
    Patent number: D724072
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: March 10, 2015
    Inventors: Wayne Jiang, Brian Jiang
  • Multi-media device stand
    Patent number: D748935
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: February 9, 2016
    Inventors: Wayne Jiang, Brian Jiang